RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

 

Article type: Editorial

Keywords: publishing, access to scientific informatio, scientific journals, internet, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Too valuable to put a price on

Too valuable to put
a price on

Access to information is essential for scientific progress, yet in many places it remains very limited. Given how easy it is to post an article on the web, where it is freely available to anyone who has access to the Internet, the current system based on subscription journals is coming increasingly into question (see Focus, p. 61). Governments, who foot the bill for most university libraries, and the charity sector, who are important sponsors of cancer research, are foremost among those

» Kathy Redmond

To read the complete article please click on the pdf icon

 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.